Mar 10, 2022
Dr. John Dobak is the President and CEO of DermTech which is leading the genomic revolution in dermatology to more accurately determine the presence of skin cancer. Their noninvasive platform changes the protocol for assessing a suspicious mole from visual review and surgically removing tissue to genomic analysis and...
Mar 10, 2022
Dr. John Dobak is the President and CEO of DermTech which is leading the genomic revolution in dermatology to more accurately determine the presence of skin cancer. Their noninvasive platform changes the protocol for assessing a suspicious mole from visual review and surgically removing tissue to genomic analysis and...
Feb 28, 2022
Tim Clackson is the President and CEO of Theseus Pharmaceuticals which has a mission to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) that are designed to hit different types of cancer cell mutations. The goals of the therapy are to delay treatment resistant cancer as well as...
Feb 28, 2022
Tim Clackson is the President and CEO of Theseus Pharmaceuticals which has a mission to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) that are designed to hit different types of cancer cell mutations. The goals of the therapy are to delay treatment resistant cancer as well as...
Feb 2, 2022
Amit Kumar is the President and CEO of Anixa Biosciences and is working on a prophylactic vaccine to prevent the onset of breast cancer rather than a therapeutic vaccine to fight the solid tumors. Anixa is also working on CAR-T therapy for solid tumors and using artificial intelligence and machine learning to discover...